There are roughly 225,000 new cases of lung cancer every year in the United States. Early diagnosis and treatment play a large role in improving outcomes. A recently developed nasal swab test could ...

CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure Despite a suspicious nodule during a ...

Lung cancer used to have grim outcomes but earlier detection is improving those odds. A new combined procedure with diagnosis ...

For many people with higher risks of developing cancer, the discovery of a nodule in the lung usually means undertaking a diagnostic journey to determine if it’s malignant or benign through invasive ...

Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated potential economic impact of CyPath® Lung for the early detection of lung cancer “Our study suggests the potential for a ...

In this case study, CyPath® Lung "Unlikely Malignancy" result supported physician’s decision to wait before ordering an invasive lung biopsy In a clinical study, noninvasive CyPath® Lung test ...

Based on audited financial results, CyPath® Lung revenue increased 87% year over year in 2025, while test units sold grew 99% ...

A revolutionary AI-powered diagnostic test for chronic obstructive pulmonary disease (COPD) is set to be introduced in GP surgeries across England from 14 April, offering a faster and more accurate ...

SAN ANTONIO - A noninvasive lung cancer diagnostic test developed by bioAffinity Technologies (NASDAQ:BIAF) helped physicians determine appropriate treatment for a 79-year-old female with a suspicious ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung ...

Lung cancer is the leading cause of death from cancer. It kills more people in the U.S. than breast, prostate, and colon ...